Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia
NCT03142568Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2018
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of sildenafil in bronchopulmonary dysplasia (BPD) (6 cohorts), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Safety as Determined by Adverse Event Experienced by Participants up to 575 days. Started Apr 2018; status: completed.
02
Drugs
sildenafil
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT03142568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03142568.